Crinetics Pharmaceuticals (CRNX)
Develops oral GPCR medicines for endocrine diseases and endocrine-related tumors.
Something off on this page? Send us feedback.
Sells PALSONIFY, a once-daily oral treatment for acromegaly, while developing paltusotine for carcinoid syndrome and atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. Product revenue comes from PALSONIFY, and most other programs remain subject to clinical and regulatory approval.
Develops and commercializes oral small-molecule medicines for endocrine diseases and endocrine-related tumors, using in-house expertise in tailoring compounds to G protein-coupled receptors. PALSONIFY (paltusotine), its first marketed product, is a once-daily oral treatment for adults with acromegaly and is approved in the U.S. and European Union. Paltusotine is also being studied for carcinoid syndrome.
Atumelnant, an oral ACTH receptor antagonist, is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. CRN09682 applies a nonpeptide drug-conjugate platform to somatostatin-receptor-expressing tumors, while discovery programs pursue other endocrine and metabolic targets.
Product revenue comes from PALSONIFY, manufacturing is outsourced, and most pipeline programs still require clinical and regulatory approval. A definitive agreement calls for Vertex Pharmaceuticals to acquire the business, subject to shareholder, regulatory, and other closing conditions.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.21B · Total debt $47.2M · Total assets $1.32B · Shareholders' equity $1.19B
- Revenue
- $25.1M
- Operating income
- −$132.5M
- Net income
- −$120.9M
No dividends on record.
| Institutions | ≈ 117.04% | 124.14M shares | |
|---|---|---|---|
| 273 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.21% | 1.28M shares | |
| 5 holders · as of Sep 1, 2026 | |||
| Adds to | 118.25% | ||
106.07M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 118.25%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.93% | 15.84M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 9.20% | 9.76M | as of Jun 30, 2026 |
Farallon Capital Management LLCInstitution | 8.48% | 8.99M | as of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 6.72% | 7.13M | as of Jun 30, 2026 |
Driehaus Capital Management LLCInstitution | 6.09% | 6.46M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 2, 2026 | Coelho Rogerio Vivaldi | director | −3,000 | $40.00 |
| Jun 17, 2026 | Stephanie Okey | director | −6,900 | $35.67 |
| Apr 8, 2026 | Jeff E. Knight | officer: Chief Dev. & Operating Officer | −85,163 | $40.10 |
| Mar 16, 2026 | Richard Scott Struthers | director, officer: President & CEO | −21,981 | $37.37 |
| Mar 16, 2026 | Stephen F. Betz | officer: Chief Scientific Officer | −10,612 | $37.37 |
- Novartis (ADR)
Dominant SSA and radioligand incumbent in acromegaly and NET therapy
- Neurocrine Biosciences
First FDA-approved CAH therapy (Crenessity) generating $301M in its launch year.
- Corcept Therapeutics
Cushing's syndrome franchise with Korlym ($761M) and pipeline relacorilant
- Pfizer
Somavert, the only approved GH receptor antagonist, in second-line acromegaly
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | $84.95 | 0.00% | $9.00B | — | — | 213.5 | +2,336.3% |
| Novartis (ADR) | $142.32 | +0.74% | $268.53B | 21.3 | 15.1 | 4.8 | +0.9% |
| Neurocrine Biosciences | $139.97 | −1.60% | $14.30B | 20.9 | 15.3 | 4.2 | +39.5% |
| Corcept Therapeutics | $112.47 | −4.28% | $12.70B | 279.8 | 28.2 | 15.3 | +31.7% |
| Pfizer | $28.06 | +0.45% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 29.1 | 15.2 | 4.5 | +17.2% |